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Epidemiology 
 Cervical cancer is the second most prevalent cancer seen in 
women worldwide 
 
 about 500,000 cases and over 270,000 deaths estimated 
annually. 
 
 cervical cancer is a STD that results from infection with certain 
high-risk, oncogenic types of the human papillomavirus (HPV). 
 
 HPV DNA is found in more 99% of invasive cervical cancers 
worldwide. 
 
 

Dispersion of Females Dominant Cancers around the world  
2012 

Publication:2012 
2012 
2012 
The Main Agent: 
 In recent years contamination with oncogene viruses (HPV-
EBV-HBV-HCV…)  is cause of  About 20% of cancers all 
around the world. 
 
 Role of persistent infection with HPV in creation of Cervical 
Cancer is fully known. 
 
 In More 99% Cases of cervical cancer HPV virus diagnosed. 
HPV : Human Papilloma Virus 
 
 
 DNA Virus – ds Circular Genome 
 Icosahedral Capsid Symmetry 
 Naked Virion 

 120 genotype of HPV identified but Only some of them can 
progress to Cervical cancer ( that named High Risk 
Genotypes) 
 
 16 And 18 are Most high risk genotypes that cause of 
more than 70 % invasive carcinoma.  
 
 Other genotypes like 6 – 11 are low risk for Cervical 
cancer (Not inconceivable) But main cause of Genital 
Warts. 
HPV Genotypes: 

Prevalence of HPV 16 & 18 Genotypes In World wide  
de Sanjosé S, Quint WG, Alemany L, et al. Human papillomavirus 
genotype attribution in invasive cervical cancer: a retrospective cross-
sectional worldwide study. Lancet Oncol.2010;11(11):1048-1056. 
HPV 16 and HPV 18 prevalence in squamous cell carcinoma and adenocarcinoma 
de Sanjosé S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in 
invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet 
Oncol.2010;11(11):1048-1056. 
Pathogenesis 
 persistent infection with an oncogenic HPV is necessary 
for carcinogenesis 
 
 In most Healthy women immune response to HPV infection 
develops after a period of months or years and results in 
adequate viral clearance. 
 
 transformation is associated with integration of the viral 
genome and epithelial cell genetic instability that occurs 
over a long period of HPV infection. 
Risk Factors: 
 
 early age of sexual activity 
 multiple sexual partners 
 exposure to other sexually transmitted diseases 
 cigarette smoking 
 oral contraceptive use 
 human immunodeficiency virus (HIV) 
 infection and immunosuppressive drug therapy. 
Clinical Aspects of HPV Infection 
 The cervix normally contains a central canal (endocervical 
canal) that Contain Columnar cells and squamous cells 
lines. 
 
 The squamo-columnar cellular junction is an active transition 
zone known as the ‘transformation zone’ (TZ). 
 
 TZ is the site of origin of the majority of cervical dysplastic 
(premalignant) lesions and carcinomatous lesions. 

Benign And Abnormal changes 
 In reproductive age women, the acid environment of the 
vagina leads to destruction of the columnar cells of the 
TZ, and induces ‘squamous metaplasia’ in the TZ. 
 
 This metaplastic change clinically considered as benign. 
 
 HPV infection can induce change from normal to 
dysplastic cellular architecture (clinically considered as 
abnormal) in the TZ and surrounding cervical portion. 
Pap Smear : First Step of Diagnosis 
 Cervical cancer screening involves the initial step of 
accessing squamous cells in the transformation zone, 
for cytological analysis (Papanicolau smear or Pap smear). 
 
 Cervical cytology reports classify dysplastic lesions as: 
 low grade squamous intraepithelial lesions (LSIL) 
 high-grade squamous intraepithelial lesions (HSIL) 
Squamous Cell Carcinoma  
((according to the Bethesda system)) 


Types of Screening 
 Conventional Pap: In a conventional Pap smear, samples are 
smeared directly onto a microscope slide after collection and 
applies a fixative. In general, the slide is sent to a laboratory 
for evaluation. 
 
 Liquid based cytology: The sample of epithelial cells is taken 
from the Transitional Zone. Liquid-based cytology uses an 
arrow-shaped brush, rather than the conventional spatula. 
The cells taken are suspended in a bottle of preservative for 
transport to the laboratory, where using Pap stains it is 
analysed.(Since the mid-1990s) 
 
Liquid-based cytology 
 Two of the types are Sure-Path (TriPath Imaging) and Thin-Prep 
(Cytyc Corp). 
 
  The media are primarily ethanol-based for Sure-Path and methanol for 
ThinPrep. 
 
  Once placed into the vial, the sample is processed at the laboratory 
into a cell thin-layer, stained, and examined by light microscopy. 
 
  The liquid sample has the advantage of being suitable for high-risk 
HPV testing and may reduce unsatisfactory specimens from 4.1% to 
2.6%. 
 
  Proper sample acquisition is crucial to the accuracy of the test, as a 
cell that is not in the sample cannot be evaluated. 
The next step: 
 the next step following a Pap smear is the assessment of 
the cervix using a microscope (colposcopy). 
 
 Colposcopy usually facilitates the obtaining of biopsies 
from the cervical lip and endocervical canal. 

Next Step: Histology 
 Histological reports of colposcopic biopsy specimens are 
reported as CIN 1, 2 or 3. 
CIN :  Cervical Intra epithelial Neoplasia 
Comparison between Cytology and Histology Grading 
Cytology limitations: 
1- The major problem is the low sensitivity of a single smear 
to detect high-grade precursor lesions (50%–70%), which 
require frequent testing. 
Cuzick J, Clavel C, Petry KU et al. Overview of the European 
and North American studies on HPV testing in primary cervical 
cancer screening. Int J Cancer 2006; 119: 1095–1101 
Cytology limitations: 
2- cytology has low reproducibility, leading to variable 
accuracy 
Nanda K, McCrory DC, Myers ER et al. Accuracy of the 
Papanicolaou test in screening for and follow-up of 
cervical cytologic abnormalities: a systematic review. 
Ann Intern Med 2000; 132: 810–819. 
Cytology limitations: 
 3- Adenocarcinoma of the cervix has not been shown to be 
prevented by Pap tests. Adenocarcinoma accounts for about 
15% of all cervical cancers. 
 
 
DeMay, M. (2007). Practical principles of cytopathology. 
Revised edition. Chicago, IL: American Society for 
Clinical Pathology Press. ISBN 978-0-89189-549-7. 
Fail To Prevention … 
Failure of prevention of cancer by the Pap test can occur for 
many reasons: 
 
 not getting regular screening 
 lack of appropriate follow up of abnormal results 
 sampling and interpretation errors 
 variable accuracy because of clinician direct diagnosis 
Pap Test at best… 
 The Pap test, when combined with a regular program of 
screening and appropriate follow-up, can reduce cervical 
cancer deaths by up to 80%. 
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, 
von Karsa L (2010). "European Guidelines for Quality Assurance in Cervical Cancer 
Screening. Second Edition—Summary Document". Annals of Oncology 21 (3): 448–
458. doi:10.1093/annonc/mdp471. PMC 2826099.PMID 20176693. 
Molecular Science Biomarkers 
The HPV life cycle and molecular events leading to cellular 
transformation, have provided insight into potential biomarkers 
that can be used as adjunctive tests to improve diagnostic 
accuracy of cervical lesions as well as, identify those patients at 
risk for progression to cancer. 
Caner Cycle 
HPV DNA Testing 
 The causal relationship between infection with HR (High 
Risk) HPV and cervical cancer has stimulated the 
application of hrHPV DNA testing 
 
 which has been proposed, either alone or in combination 
with cytology, as a means to improve existing cervical 
screening programs 
 
 The most widely used and extensively investigated 
biomarker in the management of cervical disease is HPV 
DNA testing. 

 In the past 15 years, large randomized trials designed to 
evaluate the performance of hrHPV testing have provided 
important arguments for the implementation of this assay as 
a primary screening tool. 
 
Mayrand 2007- Ronco 2008 - Naucler 2007 - Leinonen 2009 - Kitchener 2009 - Rijkaart 2012 
Commercial Available DNA Assays 
More advanced Biomarkers… 
 
Promising biomarkers involved in cervical carcinogenesis have 
already emerged. 
 
 Especially, biomarkers that indicate a shift from the 
productive phase of hrHPV infection to the transforming 
phase are valuable. 
 
 
E6-E7 Proteins Function 
E6/E7 mRNA as a Biomarker 
 HPV mRNA assays are designed to detect viral mRNAs 
encoding for the E6 and E7 proteins which are the most 
critical factors for the development of cervical cancer. 
 
 Therefore, detection of elevated E6/E7 mRNA levels in 
cervical smears has been suggested to be an attractive 
biomarker 

Commercial Available mRNA Assays 
Cellular Biomarkers 
 An alternative is the detection of cellular host genes that are 
specifically up-regulated and overexpressed, or silenced in 
cells that have undergone the shift into the transforming phase 
of hrHPV infection. 
 
 The functional inactivation of p53 and pRb oncosuppressors by 
E6 and E7 oncoproteins determines the alteration of several 
cellular pathways relevant for cell transformation and cancer 
development. 
 
 
 
p16INK4a 
 p16INK4a is a tumor-suppressor protein that inhibit 
transcription and cell-cycle progression. In most cervical 
carcinomas, the functional inactivation of pRb by HPV E7 
results in the overexpression of p16INK4a and the 
accumulation of the protein in cells. 
 
Why p16INK4a is Suitable? 
 (1) expression of p16INK4a is directly linked to the HPV 
oncogenic action and start of oncogenes. 
 
 (2) the expression of p16INK4a is independent of the HPV 
type, and therefore, genotyping does not need 
 
Ki-67 
 The proliferation antigen Ki-67,which is expressed during 
the G2 and mitotic phases of the cell cycle, has been 
demonstrated in many studies to be a reliable indicator of the 
growth of a tumor. 
 
Gene Methylation as Biomarker 
 DNA methylation is one of the epigenetic mechanisms that 
influence gene transcription, chromatin structure, genomic 
stability and … 
 
 Abnormal methylation of promoters of tumor suppressor 
genes is common in various cancers, and the analysis of 
DNA methylation as a biomarker in clinical oncology seems 
to be promising. 

Human Gene Methylation 
 In many cancers, tumor suppressor genes were found to be 
inactivated by hypermethylation of their promoter region.  
 
 Therefore, detection of hypermethylation of tumor suppressor 
genes involved in cervical cancer genesis may provide powerful 
biomarkers for cancer detection. especially as methylation has 
been detected already at precancerous stages. 
 
 In fact, a recent studies are working on the CIN Grading and 
its related Gene methylation… 
 
 
Viral Gene Methylation 
 The investigators found that elevated levels of DNA 
methylation on multiple CG sites in the L1, L2, E2, and E4 
ORFs were significantly associated with CIN2 or worse after 
accounting for multiple testing. 
 
The direct relationship between methylation status of HPV 
L1 gene and diagnosis of CIN2 seems to be relatively 
consistent in most studies. 
Screening strategy based on cytology 
Maria Lina Tornesello et al. Viral and Cellular Biomarkers in the Diagnosis of Cervical 
Intraepithelial Neoplasia and Cancer. BioMed Research International. Volume 2013, Article ID 519619 
Screening strategy based on HPV DNA tests 
Maria Lina Tornesello et al. Viral and Cellular Biomarkers in the Diagnosis of Cervical 
Intraepithelial Neoplasia and Cancer. BioMed Research International. Volume 2013, Article ID 519619 
Cervical Cancer Stages 
Treatment 
Four types of standard treatment are used: 
 
 Surgery: removing the cancer in an operation. 
 
 Radiation therapy: use high-energy x-rays or other types 
of radiation to kill cancer cells or keep them from growing. 
 
 Chemotherapy: use drugs to stop the growth of cancer cells, 
either by killing the cells or by stopping them from dividing 
 
 Targeted therapy:use drugs or other substances to identify and 
attack specific cancer cells without harming normal cells 
 
 
 
 
Human Papillomavirus Vaccines 
 GARDASIL, Merck Co. 
 June 2006 FDA approved 
 Quadrivalent (4) 
 composed of recombinant L1 protein-based viral like particles 
 HPV 6, 11, 16 and 18 
 0, 2 and 6 months 
 
 CERVARIX, GlaxoSmithKline 
 October 2009 FDA approved 
 Bivalent (2) 
 contains recombinant L1 protein 
 HPV 16 and 18 
 0, 1–2, and 6 months 
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